~~<i id='64E7B5C590'><strike id='64E7B5C590'><tt id='64E7B5C590'><pre id='64E7B5C590'></pre></tt></strike></i>~~

Home» leisure time» focus

focus

author：hotspot 2025-10-04 12:06:12 Page View：7

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dario to buy mental health app maker Twill in cash and stock deal
Next article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

explore

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

MollyFerguson/STATThisweek,anencouragingturnaroundforOcularTherapeutix,achatwithAlnylam’sCEOdefendin

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

MollyFerguson/STATAnnovisBiohadmybiotechbull%^&!meterrunningredafteritmadealatechangetothedesign